Additionally, important biomarker information such as PD-L1 expression and tumor-infiltrating lymphocyte (TIL) levels was not systematically analyzed, which weakens the biological interpretation of response mechanisms and limits the ability to identify patient subsets most likely to benefit from treatment. This evidence concerns the gene CD274 and neoplasm.